GRK6 Regulates ROS Response and Maintains Hematopoietic Stem Cell Self-Renewal
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Defective Lymphocyte Chemotaxis in Я-Arrestin2- and GRK6-Deficient Mice
Defective lymphocyte chemotaxis in -arrestin2- and GRK6-deficient mice Alan M. Fong*, Richard T. Premont*, Ricardo M. Richardson*, Yen-Rei A. Yu†, Robert J. Lefkowitz*‡§, and Dhavalkumar D. Patel*†¶ Departments of *Medicine, ‡Biochemistry, and †Immunology, and §Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC 27710 Contributed by Robert J. Lefkowitz, April 4, 2002 Lymphocyte chemotaxis is a complex process by which cells move kinase, extracellular receptor kinase, and c-jun terminal kinase within tissues and across barriers such as vascular endothelium and activation (9–12), they might also act as positive regulators of is usually stimulated by chemokines such as stromal cell-derived chemotaxis. To evaluate the role of the GRK-arrestin pathway factor-1 (CXCL12) acting via G protein-coupled receptors. Because in chemotaxis, we studied the chemotactic responses of lym- members of this receptor family are regulated (‘‘desensitized’’) by phocytes from -arrestin- and GRK-deficient mice toward G protein-coupled receptor kinase (GRK)-mediated receptor phos- gradients of stromal cell-derived factor 1 (CXCL12), a well  phorylation and -arrestin binding, we examined signaling and characterized chemokine whose receptor is CXCR4, a core- chemotactic responses in splenocytes derived from knockout mice ceptor for HIV. deficient in various -arrestins and GRKs, with the expectation that these responses might be enhanced. Knockouts of -arrestin2, Materials and Methods GRK5, and GRK6 were examined because all three proteins are :expressed at high levels in purified mouse CD3؉ T and B220؉ B Mice. The following mouse strains were used in this study splenocytes. CXCL12 stimulation of membrane GTPase activity was -arrestin2-deficient (back-crossed for six generations onto the unaffected in splenocytes derived from GRK5-deficient mice but C57͞BL6 background; ref. -
Combined Integrin Phosphoproteomic Analyses and Small Interfering RNA–Based Functional Screening Identify Key Regulators for Cancer Cell Adhesion and Migration
Published OnlineFirst April 7, 2009; DOI: 10.1158/0008-5472.CAN-08-2515 Published Online First on April 7, 2009 as 10.1158/0008-5472.CAN-08-2515 Research Article Combined Integrin Phosphoproteomic Analyses and Small Interfering RNA–Based Functional Screening Identify Key Regulators for Cancer Cell Adhesion and Migration Yanling Chen,1 Bingwen Lu,2 Qingkai Yang,1 Colleen Fearns,3 John R. Yates III,2 and Jiing-Dwan Lee1 Departments of 1Immunology, 2Chemical Physiology, and 3Chemistry, The Scripps Research Institute, La Jolla, California Abstract cytoskeletal components (2, 7) and regulation of cell survival, Integrins interact with extracellular matrix (ECM) and deliver proliferation, differentiation, cell cycle, and migration (8, 9). Understanding the mechanism by which integrins modulate these intracellular signaling for cell proliferation, survival, and motility. During tumor metastasis, integrin-mediated cell cellular activities is of significant biological importance. adhesion to and migration on the ECM proteins are required The most common cancers in human include breast cancer, for cancer cell survival and adaptation to the new microen- prostate cancer, lung cancer, colon cancer, and ovarian cancer (10, 11), and their metastasis is the leading cause of mortality in vironment. Using stable isotope labeling by amino acids in cell cancer patients, causing 90% of deaths from solid tumors (11, 12). culture–mass spectrometry, we profiled the phosphoproteo- During the process of metastasis, tumor cells leave the primary mic changes induced by the interactions of cell integrins with site, travel via blood and/or lymphatic circulatory systems, attach type I collagen, the most common ECM substratum. Integrin- to the substratum of ECM at a distant site, and establish a ECM interactions modulate phosphorylation of 517 serine, secondary tumor, accompanied by angiogenesis of the newly threonine, or tyrosine residues in 513 peptides, corresponding formed neoplasm (12). -
Investigating the Role of Cdk11in Animal Cytokinesis
Investigating the Role of CDK11 in Animal Cytokinesis by Thomas Clifford Panagiotou A thesis submitted in conformity with the requirements for the degree of Master of Science Department of Molecular Genetics University of Toronto © Copyright by Thomas Clifford Panagiotou (2020) Investigating the Role of CDK11 in Animal Cytokinesis Thomas Clifford Panagiotou Master of Science Department of Molecular Genetics University of Toronto 2020 Abstract Finely tuned spatio-temporal regulation of cell division is required for genome stability. Cytokinesis constitutes the final stages of cell division, from chromosome segregation to the physical separation of cells, abscission. Abscission is tightly regulated to ensure it occurs after earlier cytokinetic events, like the maturation of the stem body, the regulatory platform for abscission. Active Aurora B kinase enforces the abscission checkpoint, which blocks abscission until chromosomes have been cleared from the cytokinetic machinery. Currently, it is unclear how this checkpoint is overcome. Here, I demonstrate that the cyclin-dependent kinase CDK11 is required for cytokinesis. Both inhibition and depletion of CDK11 block abscission. Furthermore, the mitosis-specific CDK11p58 kinase localizes to the stem body, where its kinase activity rescues the defects of CDK11 depletion and inhibition. These results suggest a model whereby CDK11p58 antagonizes Aurora B kinase to overcome the abscission checkpoint to allow for successful completion of cytokinesis. ii Acknowledgments I am very grateful for the support of my family and friends throughout my studies. I would also like to express my deep gratitude to Wilde Lab members, both past and present, for their advice and collaboration. In particular, I am very grateful to Matthew Renshaw, whose work comprises part of this thesis. -
Comprehensive Assessment of the Association of WNK4
OPEN Comprehensive Assessment of the SUBJECT AREAS: Association of WNK4 Polymorphisms GENETICS RESEARCH RENOVASCULAR HYPERTENSION with Hypertension: Evidence from a EPIDEMIOLOGY Meta-Analysis Received Xiao-gang Guo1, Jie Ding1, Hui Xu1,2, Tian-ming Xuan1, Wei-quan Jin1, Xiang Yin1, Yun-peng Shang1, 22 April 2014 Fu-rong Zhang1, Jian-hua Zhu1 & Liang-rong Zheng1 Accepted 15 September 2014 1Department of Cardiology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China, Published 2Xiuzhou District, Gaozhao Street Community Health Service Center, Jiaxing 314031, China. 30 September 2014 The relationship between with-no-lysine [K] kinase 4 (WNK4) gene polymorphisms and hypertension has been widely investigated, However, the studies yielded contradictory results. To evaluate these inconclusive Correspondence and findings comprehensively, we therefore performed a meta-analysis. Ten articles encompassing 16 requests for materials independent case-control studies with 6089 hypertensive cases and 4881 normotensive controls were should be addressed to selected for this meta-analysis. Four WNK4 gene polymorphisms were identified (G1155942T, G1156666A, X.-G.G. (gxg22222@ T1155547C, and C6749T). The results showed statistically significant associations of G1155942T polymorphism (allelic genetic model: odds ration or OR51.62, 95% confidence interval or CI: 1.11–2.38, zju.edu.cn) P50.01; dominant model: OR51.85, 95% CI: 1.07–3.19, P50.03) and C6749T polymorphism (allele contrast: OR52.04, 95% CI: 1.60–2.59, P,0.01; dominant model: OR52.04, 95%CI: 1.59–2.62, P,0.01; and homozygous model: OR55.01, 95% CI: 1.29–19.54, P50.02) with hypertension risk. However, neither C1155547T nor G1156666A was associated significantly with hypertension susceptibility. -
The Emerging Roles and Therapeutic Potential of Cyclin- Dependent Kinase 11 (CDK11) in Human Cancer
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 26 Review The emerging roles and therapeutic potential of cyclin- dependent kinase 11 (CDK11) in human cancer Yubing Zhou1,2, Jacson K. Shen2, Francis J. Hornicek2, Quancheng Kan1 and Zhenfeng Duan1,2 1 Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of China 2 Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA, United States of America Correspondence to: Quancheng Kan, email: [email protected] Correspondence to: Zhenfeng Duan, email: [email protected] Keywords: CDK11, CDKs inhibitor, cell cycle, therapeutic target, cancer therapy Received: January 20, 2016 Accepted: March 28, 2016 Published: March 31, 2016 ABSTRACT Overexpression and/or hyperactivation of cyclin-dependent kinases (CDKs) are common features of most cancer types. CDKs have been shown to play important roles in tumor cell proliferation and growth by controlling cell cycle, transcription, and RNA splicing. CDK4/6 inhibitor palbociclib has been recently approved by the FDA for the treatment of breast cancer. CDK11 is a serine/threonine protein kinase in the CDK family and recent studies have shown that CDK11 also plays critical roles in cancer cell growth and proliferation. A variety of genetic and epigenetic events may cause universal overexpression of CDK11 in human cancers. Inhibition of CDK11 has been shown to lead to cancer cell death and apoptosis. Significant evidence has suggested that CDK11 may be a novel and promising therapeutic target for the treatment of cancers. This review will focus on the emerging roles of CDK11 in human cancers, and provide a proof-of-principle for continued efforts toward targeting CDK11 for effective cancer treatment. -
Supplementary Table 1. in Vitro Side Effect Profiling Study for LDN/OSU-0212320. Neurotransmitter Related Steroids
Supplementary Table 1. In vitro side effect profiling study for LDN/OSU-0212320. Percent Inhibition Receptor 10 µM Neurotransmitter Related Adenosine, Non-selective 7.29% Adrenergic, Alpha 1, Non-selective 24.98% Adrenergic, Alpha 2, Non-selective 27.18% Adrenergic, Beta, Non-selective -20.94% Dopamine Transporter 8.69% Dopamine, D1 (h) 8.48% Dopamine, D2s (h) 4.06% GABA A, Agonist Site -16.15% GABA A, BDZ, alpha 1 site 12.73% GABA-B 13.60% Glutamate, AMPA Site (Ionotropic) 12.06% Glutamate, Kainate Site (Ionotropic) -1.03% Glutamate, NMDA Agonist Site (Ionotropic) 0.12% Glutamate, NMDA, Glycine (Stry-insens Site) 9.84% (Ionotropic) Glycine, Strychnine-sensitive 0.99% Histamine, H1 -5.54% Histamine, H2 16.54% Histamine, H3 4.80% Melatonin, Non-selective -5.54% Muscarinic, M1 (hr) -1.88% Muscarinic, M2 (h) 0.82% Muscarinic, Non-selective, Central 29.04% Muscarinic, Non-selective, Peripheral 0.29% Nicotinic, Neuronal (-BnTx insensitive) 7.85% Norepinephrine Transporter 2.87% Opioid, Non-selective -0.09% Opioid, Orphanin, ORL1 (h) 11.55% Serotonin Transporter -3.02% Serotonin, Non-selective 26.33% Sigma, Non-Selective 10.19% Steroids Estrogen 11.16% 1 Percent Inhibition Receptor 10 µM Testosterone (cytosolic) (h) 12.50% Ion Channels Calcium Channel, Type L (Dihydropyridine Site) 43.18% Calcium Channel, Type N 4.15% Potassium Channel, ATP-Sensitive -4.05% Potassium Channel, Ca2+ Act., VI 17.80% Potassium Channel, I(Kr) (hERG) (h) -6.44% Sodium, Site 2 -0.39% Second Messengers Nitric Oxide, NOS (Neuronal-Binding) -17.09% Prostaglandins Leukotriene, -
Targeting CDK2 Overcomes Melanoma Resistance Against BRAF and Hsp90 Inhibitors
Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors Downloaded from: https://research.chalmers.se, 2019-05-11 18:56 UTC Citation for the original published paper (version of record): Azimi, A., Caramuta, S., Seashore-Ludlow, B. et al (2018) Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors Molecular Systems Biology, 14(3) http://dx.doi.org/10.15252/msb.20177858 N.B. When citing this work, cite the original published paper. research.chalmers.se offers the possibility of retrieving research publications produced at Chalmers University of Technology. It covers all kind of research output: articles, dissertations, conference papers, reports etc. since 2004. research.chalmers.se is administrated and maintained by Chalmers Library (article starts on next page) Published online: March 5, 2018 Article Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors Alireza Azimi1,†, Stefano Caramuta1,†, Brinton Seashore-Ludlow2,†, Johan Boström3 , Jonathan L Robinson4, Fredrik Edfors5, Rainer Tuominen1, Kristel Kemper6, Oscar Krijgsman6 , Daniel S Peeper6 , Jens Nielsen4 , Johan Hansson1, Suzanne Egyhazi Brage1, Mikael Altun3 , Mathias Uhlen5 & Gianluca Maddalo5,* Abstract Introduction Novel therapies are undergoing clinical trials, for example, the Malignant melanoma has the highest somatic mutational rate Hsp90 inhibitor, XL888, in combination with BRAF inhibitors for among cancers (Alexandrov et al, 2013) and its incidence is steadily the treatment of therapy-resistant melanomas. Unfortunately, our increasing (https://training.seer.cancer.gov/melanoma/intro/). In data show that this combination elicits a heterogeneous response the majority of the cases, it harbors BRAF (~60%) or NRAS (~20%) in a panel of melanoma cell lines including PDX-derived models. -
High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype
Supplementary Information High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype Håkon Reikvam 1,2,*, Elise Aasebø 1, Annette K. Brenner 2, Sushma Bartaula-Brevik 1, Ida Sofie Grønningsæter 2, Rakel Brendsdal Forthun 2, Randi Hovland 3,4 and Øystein Bruserud 1,2 1 Department of Clinical Science, University of Bergen, 5020, Bergen, Norway 2 Department of Medicine, Haukeland University Hospital, 5021, Bergen, Norway 3 Department of Medical Genetics, Haukeland University Hospital, 5021, Bergen, Norway 4 Institute of Biomedicine, University of Bergen, 5020, Bergen, Norway * Correspondence: [email protected]; Tel.: +55-97-50-00 J. Clin. Med. 2019, 8, x 2 of 36 Figure S1. Mutational studies in a cohort of 71 AML patients. The figure shows the number of patients with the various mutations (upper), the number of mutations in for each patient (middle) and the number of main classes with mutation(s) in each patient (lower). 2 J. Clin. Med. 2019, 8, x; doi: www.mdpi.com/journal/jcm J. Clin. Med. 2019, 8, x 3 of 36 Figure S2. The immunophenotype of primary human AML cells derived from 62 unselected patients. The expression of the eight differentiation markers CD13, CD14, CD15, CD33, CD34, CD45, CD117 and HLA-DR was investigated for 62 of the 71 patients included in our present study. We performed an unsupervised hierarchical cluster analysis and identified four patient main clusters/patient subsets. The mutational profile for each f the 62 patients is also given (middle), no individual mutation of main class of mutations showed any significant association with any of the for differentiation marker clusters (middle). -
Comprehensive Assessment of Indian Variations in the Druggable Kinome Landscape Highlights Distinct Insights at the Sequence, Structure and Pharmacogenomic Stratum
SUPPLEMENTARY MATERIAL Comprehensive assessment of Indian variations in the druggable kinome landscape highlights distinct insights at the sequence, structure and pharmacogenomic stratum Gayatri Panda1‡, Neha Mishra1‡, Disha Sharma2,3, Rahul C. Bhoyar3, Abhinav Jain2,3, Mohamed Imran2,3, Vigneshwar Senthilvel2,3, Mohit Kumar Divakar2,3, Anushree Mishra3, Priyanka Banerjee4, Sridhar Sivasubbu2,3, Vinod Scaria2,3, Arjun Ray1* 1 Department of Computational Biology, Indraprastha Institute of Information Technology, Okhla, India. 2 Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India. 3 CSIR-Institute of Genomics and Integrative Biology, Mathura Road, Delhi-110020, India. 4 Institute for Physiology, Charite-University of Medicine, Berlin, 10115 Berlin, Germany. ‡These authors contributed equally to this work. * [email protected] TABLE OF CONTENTS Name Title Supplemental_Figure_S1 Fauchere and Pliska hydrophobicity scale for variations in structure data Supplemental_Figure_S2 Phenotypic drug-drug correlogram Supplemental_Table_S1 545 kinase coding genes used in the study Supplemental_Table_S2 Classes and count of kinase coding genes Supplemental_Table_S3 Allele frequency Indian v/s other populations from 1000 genome data(1000g2015). Supplemental_Table_S4 IndiGen Structure Data- consisting of 12 genes and their 22 variants Supplemental_Table_S5 Genes, PDB ids, mutations in IndiGen data and associated drugs (FDA approved) Supplemental_Table_S6 Data used for docking and binding pocket similarity analysis Supplemental_Table_S7 -
Selective Engagement of G Protein Coupled Receptor Kinases (Grks) Encodes Distinct Functions of Biased Ligands
Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands David A. Zidara, Jonathan D. Violina, Erin J. Whalena, and Robert J. Lefkowitza,b,c,1 Departments of aMedicine, bBiochemistry, and cHoward Hughes Medical Institute, Duke University Medical Center, Durham, NC 27710 Contributed by Robert J. Lefkowitz, April 24, 2009 (sent for review February 13, 2009) CCL19 and CCL21 are endogenous agonists for the seven-trans- to be uniquely required for -arrestin-mediated MAP kinase membrane receptor CCR7. They are equally active in promoting G signaling (16, 17). protein stimulation and chemotaxis. Yet, we find that they result The chemokine receptor CCR7 is particularly important for in striking differences in activation of the G protein-coupled immune responses requiring the coordinated interaction of receptor kinase (GRK)/ß-arrestin system. CCL19 leads to robust various cell types within lymphoid tissues (18, 19). It is unique CCR7 phosphorylation and -arrestin2 recruitment catalyzed by for its high expression on mature, naïve T lymphocytes and is both GRK3 and GRK6 whereas CCL21 activates GRK6 alone. This vital for homeostatic recirculation of these cells through sec- differential GRK activation leads to distinct functional conse- ondary lymphoid tissues. CCR7 has two endogenous ligands, quences. Although each ligand leads to -arrestin2 recruitment, CCL19 and CCL21, which have evolved from a series of complex only CCL19 leads to redistribution of -arrestin2-GFP into endocytic gene duplications and retain 32% amino acid sequence homol- vesicles and classical receptor desensitization. In contrast, these ago- ogy (20–22). They are predicted to be structurally similar except  nists are both capable of signaling through GRK6 and -arrestin2 to that CCL21 has a conserved motif consisting of an additional 37 ERK kinases. -
G Protein-Coupled Receptor Kinase 4 Gene Variants in Human Essential Hypertension
G protein-coupled receptor kinase 4 gene variants in human essential hypertension Robin A. Felder*, Hironobu Sanada*†, Jing Xu‡, Pei-Ying Yu‡, Zheng Wang‡, Hidetsuna Watanabe*, Laureano D. Asico*, Wei Wang‡, Shaopeng Zheng‡, Ikuyo Yamaguchi‡, Scott M. Williams§, James Gainer¶, Nancy J. Brown¶, Debra Hazen-Martinʈ, Lee-Jun C. Wong**, Jean E. Robillard††, Robert M. Carey‡‡, Gilbert M. Eisner‡, and Pedro A. Jose‡ *Department of Pathology, University of Virginia Health Sciences Center, Charlottesville, VA 22908; ‡Department of Pediatrics and Physiology and Biophysics, Georgetown University Medical Center, Washington, DC 20007; §Department of Microbiology, Meharry Medical College, Nashville, TN 37208; ¶Department of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232; ʈDepartment of Pathology, Medical University of South Carolina, Charleston, SC 29403; **Institute for Molecular and Human Genetics, Georgetown University Medical Center, Washington, DC 20007; ††Department of Pediatrics, University of Michigan College of Medicine, Ann Arbor, MI 48109; and ‡‡Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, VA 22908 Communicated by Maria Iandolo New, Weill Medical College of Cornell University, New York, NY, December 21, 2001 (received for review August 10, 2001) Essential hypertension has a heritability as high as 30–50%, but its abnormal renal sodium transporters (3, 8, 13, 17). Also, the genetic cause(s) has not been determined despite intensive inves- coding region of the D1 receptor is unchanged in hypertensive tigation. The renal dopaminergic system exerts a pivotal role in subjects (16), as well as in rodents with genetic hypertension maintaining fluid and electrolyte balance and participates in the (unpublished studies). pathogenesis of genetic hypertension. -
Detection of Selection Signatures in Farmed Coho Salmon (Oncorhynchus Kisutch) Using Dense Genome‑Wide Information M
www.nature.com/scientificreports OPEN Detection of selection signatures in farmed coho salmon (Oncorhynchus kisutch) using dense genome‑wide information M. E. López1, M. I. Cádiz2, E. B. Rondeau3, B. F. Koop3 & J. M. Yáñez2,4* Animal domestication and artifcial selection give rise to gradual changes at the genomic level in populations. Subsequent footprints of selection, known as selection signatures or selective sweeps, have been traced in the genomes of many animal livestock species by exploiting variation in linkage disequilibrium patterns and/or reduction of genetic diversity. Domestication of most aquatic species is recent in comparison with land animals, and salmonids are one of the most important fsh species in aquaculture. Coho salmon (Oncorhynchus kisutch), cultivated primarily in Chile, has been subjected to breeding programs to improve growth, disease resistance traits, and fesh color. This study aimed to identify selection signatures that may be involved in adaptation to culture conditions and traits of productive interest. To do so, individuals of two domestic populations cultured in Chile were genotyped with 200 thousand SNPs, and analyses were conducted using iHS, XP‑EHH and CLR. Several signatures of selection on diferent chromosomal regions were detected across both populations. Some of the identifed regions under selection contained genes such anapc2, alad, chp2 and myn, which have been previously associated with body weight in Atlantic salmon, or sec24d and robo1, which have been associated with resistance to Piscirickettsia salmonis in coho salmon. Findings in our study can contribute to an integrated genome‑wide map of selection signatures, to help identify the genetic mechanisms of phenotypic diversity in coho salmon.